Latest Janssen Biotech Inc. Stories
HORSHAM, Pa., Nov. 8, 2012 /PRNewswire/ -- While the devastating physical effects of prostate cancer are widely known, the psychological impact of the disease is a silent struggle for many men. Janssen Biotech, Inc. releases the results of its "Mind Over Manhood: Misconceptions About Prostate Cancer" survey conducted by Wakefield Research, which uncovers both a surprising lack of awareness and a profound emotional impact of the disease on men. The survey reveals a significant gap...
SPRING HOUSE, Pa., Oct. 17, 2012 /PRNewswire/ -- Findings from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial evaluating the efficacy and safety of STELARA(®) (ustekinumab) in the treatment of moderate to severe Crohn's disease appeared today in The New England Journal of Medicine. The results showed that among patients who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist, a significantly greater...
SUNNYVALE, Calif., Oct. 15, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the international, randomized Phase III clinical trial (CLL3001) of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a third $50 million milestone payment...
HORSHAM, Pa., Oct. 1, 2012 /PRNewswire/ -- Janssen Biotech, Inc. ("Janssen") announced today that it has entered into a license agreement with Astellas Pharma Inc. ("Astellas") for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for moderate-to-severe rheumatoid arthritis (RA), following a successful Phase 2a study...
HORSHAM, Pa., Sept. 18, 2012 /PRNewswire/ -- Janssen Biotech, Inc. announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of an investigational intravenous formulation of the anti-tumor necrosis factor (TNF)-alpha SIMPONI(®) (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). An estimated 1.5 million Americans are living with RA,[1] a chronic...
LIONVILLE, Pa., Sept. 4, 2012 /PRNewswire/ -- West (NYSE: WST), a leading global manufacturer of components and systems for injectable drug delivery, today announced an agreement with Janssen Biotech, Inc. to collaborate on the development and manufacturing of an innovative self-injection product. The technology, developed by Janssen Biotech, has been specifically designed to meet the needs of patients by facilitating easier self-injection of pharmaceutical and biologic drug products....
SUNNYVALE, Calif., Aug. 20, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the clinical trial, SPARK (MCL2001), of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL) has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a second $50 million milestone payment obligation from Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, worldwide...
In the news release, Pharmacyclics® Triggers Significant Milestone Payment and Provides Clinical Program Update, issued 01-Aug-2012 by Pharmacyclics, Inc. over PR Newswire, we are advised by the company that the first paragraph, last sentence, should read "calendar 2012" rather than "calendar 2013" as originally issued inadvertently. The complete, corrected release follows: Pharmacyclics® Triggers Significant Milestone Payment and Provides Clinical Program Update SUNNYVALE,...
SUNNYVALE, Calif., Aug. 1, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the international Phase III randomized, multicenter, open-label clinical trial, RESONATE(TM) (PCYC-1112), of ibrutinib versus ofatumumab for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) initiated by Pharmacyclics has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a $50 million...
HORSHAM, Pa. and LEIDEN, Netherlands, July 16, 2012 /PRNewswire/ -- Janssen Biotech, Inc. and Janssen Biologics B.V. announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) requesting approval of SIMPONI® (golimumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response...
